Renalytix plc
("Renalytix" or the "Company")
Result of General Meeting
LONDON and SALT LAKE CITY, 22 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in Proxy Statement that contains the Notice of General Meeting, which was sent to shareholders on 3 April 2024.
The results of the GM are detailed below:
|
Resolution |
|
Votes in favour |
% |
|
Votes against |
% |
|
Votes withheld |
|
|
|
|
|
|
|
|
|
|
|
Resolution 1 |
|
50,091,780 |
98.77% |
|
621,329 |
1.23% |
|
120,431 |
|
Resolution 2 |
|
45,880,130 |
90.47% |
|
4,832,979 |
9.53% |
|
120,431 |
|
Resolution 3 |
|
50,072,092 |
98.74% |
|
641,404 |
1.26% |
|
120,044 |
|
Resolution 4 |
|
45,853,622 |
90.42% |
|
4,859,914 |
9.58% |
|
120,004 |
For further information, please contact:
|
Renalytix plc James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser to the Company) Nicholas Moore / Alex Price / Nick Harland / Samira Essebiya / Harry Billen |
Tel: 02077107600 |
|
|
|
|
Investec Bank plc Gary Clarence / Shalin Bhamra |
Tel: 020 7597 4000 |
|
|
|
|
Walbrook PR Limited Paul McManus / Alice Woodings / Charlotte Edgar |
Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07407 804 654 / 07884 664 686 |
|
|
|
|
CapComm Partners Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
